Curriculum Vitae

Personal information

Camilla Aertebjerg Baek

Work experience

1. Employer: Danish Medicines Agency
   - Start date: 010124
   - End date:
   - Position: Clinical pharmacology assessor
   - Activities: Participating in rapporteur teams assessing clinical pharmacology dossiers for EMA marketing applications.
2. Employer: Danish Medicines Agency
   - Start date: 062017
   - End date: 311223
   - Position: Nonclinical Assessor
   - Activities: Participating in rapporteur teams by assessing nonclinical dossiers for EMA marketing applications as well as national and DCP/MRP applications. Provide scientific advice on non_clinical aspects both at national and CHMP level.
   - Country: Denmark
3. Employer: Novo Nordisk A/S
   - Start date: 112013
   - End date: 032017
   - Position: Senior Scientist Pharmacokineticist
   - Activities: Toxicokinetics, Pharmacokinetic modelling & Simulations, support to study design of toxicity, safety pharmacology and phase 1 studies on peptides and large molecules
   - Country: Denmark
4. Employer: Zealand Pharma A/S
   - Start date: 042008
   - End date: 102013
   - Position: Senior Scientist
   - Activities: Bioanalysis (Mass Spectrometry) & Pharmacokinetics support to discovery and early development Projects on peptides
   - Country: Denmark
5. Employer: NeuroSearch A/S
   - Start date: 121996
   - End date: 032008
   - Position: Research Scientist
   - Activities: Bioanalysis (mass spectrometry), metabolite ID, Mass Balance (animals and humans), Disposition, Drug Metabolism and Pharmacokinetics studies on small molecules
   - Country: Denmark

Education and training

1. Subject: Royal Danish School of Pharmacy
   - Start date: 121993
   - End date: 111996
   - Qualification: Ph.D. (Analytical Chemistry & Metabolism)
   - Organisation: Institute of Pharmaceutical and Analytical Siences. Subjects/Skills: Metabolic profiling of skatole, NMR, Radiochromatography, Solid phase extraction, Preparative HPLC Characterising components of boar taint in pig fat, GC_MS, GC_FID/Sniffing, Identification of volatile compounds in boar fat
   - Country: Denmark
2. Subject: Royal Danish School of Pharmacy
   - Start date: 081986
   - End date: 061992
   - Qualification: Master in Pharmacy (Cand.pharm.)
   - Organisation: Royal Danish School of Pharmacy
   - Country: Denmark

Additional information

Publications

Articles:

Gordon Monro, Camilla Æ. Bæk, Helle K. Erichsen, Alexander N. Nielsen, Elsebeth Ø. Nielsen, Jørgen Scheel_Kruger, Pia Weikop, Dan Peters: The novel compound 1_[10_(€_3_Phenyl_allyl)_3,10_diaza_bicyclo[4.3.1]dec_3_yl]_propan_1_one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined µ_opioid receptor agonist and monoamine reuptake inhibitor tramadol. Neuropharmacology 2007.

Camilla Æ. Bæk, Jens Hansen_Møller, Christian Friis, Claus Cornett, and Steen Honoré Hansen: Identification of Selected Metabolites of Skatole in Plasma and Urine from Pigs. J. Agric. Food Chem., 45, 2332, 1997.

Patents:

Patent: WO 2011/006497 Patent owner: Zealand Pharma A/S Inventors: Eddi Meier; Ditte Riber; Jens Rosengren

Daugaard; Marie Skovgaard; Camilla Ærtebjerg Bæk; Gita Kampen; Jakob Lind Tolborg Title: Acylated Glucagon Analogues

Patent: 173_000_DK Patent owner: Poseidon Pharmaceuticals A/S Inventors: Lars Siim Madsen, Camilla Ærtebjerg Bæk, Anette Lauritsen, Maria Belvisi and Søren Peter Olesen. Title: Use of benzimidazol_2_one derivatives for treating obstructive or inflammatory airway disease. Patent: 171085 B1 Patent owner: The Danish Meat Research Institute Inventors: Jens Hansen_Møller, Christian Friis, Camilla Ærtebjerg Bæk, Steen Honoré Hansen Title: Fremgangsmåde til at undersøge grise for at bestemme om de er egnet til avl eller formering samt anvendelse af dyr eller sæd.

Lectures:

Bæk, C. E., Hansen_Møller, J., Friis, C., and Hansen, S.H. (1995). Identification and quantification of selected metabolites of skatole: Possibilities for metabolic profiling of pigs. Proceedings of a Meeting of the E.A.A.P. Working Group: Production and Utilization of Meat from Entire Male Pigs, pp. 27–29. September 1995; Milton Keynes, UK. Milton Keynes: INRA and MLC (184 p.).

Posters:

Fosgerau, K, Skovgaard, M., Larsen, S.A., Bæk, C.Æ., Meier, E., Groendahl, C., and Bak, H.H. Combination of long_acting insulin with the dual GluGLP_1 agonist ZP2929 causes improved glycemic control without body weight gain in db/db mice. American Diabetes Association's (ADA) 71st Scientific Sessions, San Diego, June 2011.

Abrar, M., Allanson, J., Bæk, C.Æ. and Davuluri, P. Development of a high sensitivity on_line extraction LC_MS/MS (Xevo TQ_S) method for the determination of GLP_1_glucagon agonist (ZP2929) in human plasma. European Bioanalysis Forum – Large meets small, Brussels, June 2011.

Bæk, C.Æ., Jensen, A.L., Malik, N. & Hemsley, M. Bioanalytical methods using LC_MS/MS for determination of the GLP_1_Glu dual agonist ZP2929 in plasma. European Bioanalysis Forum – Large meets small, Brussels, June 2011.

Daugaard, J.R., Meier, E., Riber, D., Bæk, C.Æ. and Larsen, K.S. The New Dual Glucagon_GLP_1 Agonist ZP2929 Acutely Improves Glycemic control in High Fat Fed C57BL/6J mice. Keystone, 12_17 January, 2011. Daugaard, J.R., Riber, D., Larsen, K., Meier, E., Bæk, C.Æ., Kampen, G. The New Dual Glucagon_GLP_1 Agonist ZP2929 Improves Glycemic Control and Reduces Body Weight in Murine Models of Obesity and insulin resistance. EASD 46th Annual Meeting, Stockholm, Sweden, Sep. 2010

Daugaard, J.R., Meier, E., Riber, D., Bæk, C.Æ. and Larsen, K.S. The new dual GluGLP_1 agonist ZP2929 improves glycemic control and reduces body weight in murine models of obesity and type 2 diabetes. ADA, Orlando, June 2010.

Bæk, C.Æ., Hansen_Møller, J., Friis, C., Honoré Hansen, S. Assay of selected metabolites of skatole in plasma from pigs. HPLC, San Francisco, 1996.

Projects

Non-clinical activities on peptides and large molecule drugs. Pharmacokinetic modelling and simulations using non-clinical data. Prediction of PK/PD in humans from non-clinical data for safety assessment and dose setting prior to Phase 1. Research, non-clinical development and early clinical activities on glucagon analogues, bioanalysis of peptides (mass spectrometry). ADME, Drug Metabolism & Pharmacokinetics activities on small molecule drug candidates for CNS and selected peripheral ion channel targets, bioanalysis of small molecules (mass spectrometry).

Memberships

Other Relevant Information